Calcitriol, Etelcalcetide, and Paricalcitol Injections — CPB 0022 | AETNA Coverage Update

Aetna modified CPB 0022 for calcitriol, etelcalcetide (Parsabiv), and paricalcitol (Zemplar) injections, effective February 13, 2026. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its calcitriol injection coverage policy under CPB 0022 in the Aetna system, with changes affecting HCPCS codes J0606 (etelcalcetide), J0636 (calcitriol), and J2501 (paricalcitol). This policy applies to commercial medical plans only — if your patients are on Medicare, Aetna points you to its separate Medicare Part B criteria. The practical effect: stricter lab thresholds and specialist prescription requirements apply to all three agents. If you bill these drugs for hemodialysis patients, review your documentation workflow now.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Calcitriol, Etelcalcetide, and Paricalcitol Injections
Policy Code	CPB 0022
Change Type	Modified
Effective Date	February 13, 2026
Impact Level	High — all three drugs require specialist prescriber documentation and lab threshold evidence
Specialties Affected	Nephrology, Endocrinology, Dialysis facilities
Key Action	Confirm all prior authorization submissions for J0606 include corrected serum calcium ≥ 8.4 mg/dL and elevated iPTH documentation before submitting claims

---

Aetna Calcitriol, Etelcalcetide, and Paricalcitol Coverage Criteria and Medical Necessity Requirements 2026

The Aetna calcitriol injection coverage policy under CPB 0022 covers three drugs — but each one has its own medical necessity bar, and they are not interchangeable from a documentation standpoint.

Calcitriol (J0636)

Aetna covers calcitriol injection for members with chronic kidney disease (CKD) on hemodialysis who have hypocalcemia, secondary hyperparathyroidism, or both. The prescription must come from — or be in documented consultation with — an endocrinologist or nephrologist. Any other indication is denied as experimental.

For continuation of therapy, you need documented evidence of benefit: improvement or stabilization of serum calcium (CPT 82310–82331) and phosphorus levels (CPT 84100), or a measurable decrease in parathyroid hormone (PTH) from baseline (CPT 83970). Without those lab values in the record, you're billing into a denial.

Etelcalcetide / Parsabiv (J0606) — Prior Authorization Required

Etelcalcetide carries the most specific lab thresholds in this policy. Aetna considers J0606 medically necessary only when the member meets both of these criteria:

#	Covered Indication Copy
1	Serum calcium (corrected for albumin) ≥ 8.4 mg/dL
2	Intact parathyroid hormone (iPTH) above the laboratory reference range

Both conditions must be met. One is not enough. If your documentation only shows elevated iPTH without the corrected calcium value, the prior authorization will come back denied.

Etelcalcetide also requires precertification for all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277. This is not optional — it applies broadly across commercial plans.

For continuation, reauthorization requires documented iPTH decrease from pretreatment baseline. Build that lab pull into your renewal workflow before the reauth window opens.

Paricalcitol / Zemplar (J2501)

Aetna covers paricalcitol injection for prevention and treatment of secondary hyperparathyroidism in CKD members on hemodialysis. Like calcitriol, the prescription must involve an endocrinologist or nephrologist.

Continuation of therapy requires documented iPTH decrease from pretreatment baseline — same standard as etelcalcetide. If iPTH levels aren't tracked longitudinally in the chart, reauthorization requests stall.

---

Aetna Calcitriol and Paricalcitol Exclusions and Non-Covered Indications

Aetna's language here is consistent across all three drugs: any indication not listed in the policy is considered experimental, investigational, or unproven. There are no carve-outs or gray areas listed.

That means off-label use — even if clinically supported — will not pass Aetna's medical necessity review under this coverage policy. If you're billing J0636, J0606, or J2501 for anything other than the specific indications listed (hypocalcemia or secondary hyperparathyroidism in hemodialysis-dependent CKD members), expect a claim denial.

The policy also flags cinacalcet (J0604) as not covered for concurrent use with etelcalcetide. If a patient is on both, the combination is excluded. Check your claims for J0604 + J0606 together and resolve those before billing.

---

Coverage Indications at a Glance

---

Aetna Calcitriol, Etelcalcetide, and Paricalcitol Billing Guidelines and Action Items 2026

The effective date of February 13, 2026, is behind us. If your team hasn't audited claims and PA submissions against these criteria, do it now. Here's your action list.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Calcitriol, Etelcalcetide, and Paricalcitol Under CPB 0022

HCPCS Codes Covered When Selection Criteria Are Met

Other HCPCS Codes Related to CPB 0022

CPT Codes Related to CPB 0022

These codes represent the lab work that drives medical necessity decisions. They are supporting codes — not the drug codes — but they appear on claims and in documentation tied to coverage determinations.

Key ICD-10-CM Diagnosis Codes

These are among the diagnosis codes referenced in CPB 0022. The full list contains 192 codes. The codes most directly relevant to the covered indications are listed first.

The full ICD-10-CM list also includes sepsis (A40.0–A41.9), malignant neoplasms (C00.0–D09.9), myelodysplastic syndromes (D46.0–D46.9), and cystic fibrosis (E84.0–E84.9) code ranges. Review the complete code set at app.payerpolicy.org/p/aetna/0022 to confirm which codes apply to your specific patient population.

---